EBITDA Multiples Hit a Five-Year High in Q1 2026, but the Sponsor-Strategic Spread Is the Real Signal

The Q1 2026 deal data is in, and it is the kind of mixed picture that rewards careful reading. The global median EV to EBITDA multiple expanded to 10.7x on a trailing twelve-month basis, the highest reading since 2021. Total Q1 deal value reached an estimated $1.6 trillion, up 50.6 percent year over year. At the same time, the spread between what sponsors paid and what public strategics paid widened to 3.4 turns of EBITDA. For business owners thinking about a sale in 2026, the headline multiple matters less than understanding why those buyer types are paying such different prices and how to position for the higher end of the range.

What the Numbers Actually Show

The aggregate data deserves a moment of unpacking. The 10.7x median is a global, all-sector figure spanning public take-privates, strategic combinations, and sponsor-led deals. Within that aggregate, sponsors paid an average of 12.0x EV to EBITDA through Q3 2025, the most recent period with comparable data. Private strategic buyers paid an average of 9.8x. Public strategic buyers paid an average of 8.6x. US middle-market data, looking at deals between $10 million and $500 million in enterprise value, settled at roughly 9.8x in 2025 with similar premium and typical bands expected to hold in 2026. About 27 percent of advisors surveyed by Capstone expect multiples to expand further in 2026, while two thirds expect little to no change.

The implication is straightforward. If you are running a sale process in 2026, the difference between a sponsor bid and a public strategic bid could easily be 30 to 40 percent of enterprise value on the same EBITDA. Designing the process around that reality is one of the most important decisions an owner makes.

Why Sponsors Are Paying More

A few structural factors explain the sponsor premium. Direct lending markets have remained competitive even as banks pulled back, so sponsors that can stack five turns or more of EBITDA in unitranche debt at reasonable spreads can pay up on equity and still hit fund-level returns. Aggregate dry powder across PE remains elevated, and limited partners are pressing for capital deployment, which increases willingness to stretch on price for the right asset. Sponsor portfolio companies have largely worked through the higher-rate environment of 2023 and 2024, so operating teams are more confident in synergy capture and value creation playbooks than they were two years ago. And when a hold extends past year five, sponsors increasingly have the option to roll the asset into a continuation vehicle rather than sell, which changes the calculus on entry price: a higher entry can be defended if the exit horizon is flexible.

Public strategics, by contrast, face a more disciplined buyer set. Their CFOs have to defend deals to public shareholders, rating agencies, and quarterly earnings consensus. That discipline shows up in price.

How Sellers Should Use This

The takeaway for owners is not "sell to a sponsor." Sponsor processes have their own complications: longer diligence, more aggressive working capital and indemnity terms, and rep and warranty insurance economics that often come back at the seller. The takeaway is to design a competitive process that includes both buyer types, lets each test their math against the other, and forces real price discovery.

Three tactical points matter. Run a structured process with both buyer types in the same lane: strategic buyers and sponsors do diligence differently, and a clean process that gives both buyer types fair access to the data room, management presentations, and Q&A creates the competitive tension that lifts price. Stress test your quality of earnings analysis early: pre-sale QoE work catches adjustments before the buyer does, and in 2026, with diligence scrutiny still elevated, sellers who skip this step are giving away leverage at the negotiating table. Pay attention to the "buyer type tax" in deal terms: sponsor deals often come with tighter working capital pegs, more aggressive escrows, and earnouts on contingent value, while strategic deals often offer cleaner terms with more cash certainty. The headline EV is only part of the price; the deal terms can move actual proceeds materially.

What's Driving the Median Higher

Beyond the buyer-type spread, several factors are pushing the aggregate multiple to a five-year high. Software, semiconductors, data center services, and AI-adjacent infrastructure deals are pulling deal multiples up across technology, paying meaningful premiums to the broader market. Established branded pharma and durable healthcare services have re-rated as investors recalibrate to long-term cash flow durability, with Sun Pharma's $11.75 billion bid for Organon at a 24 percent premium serving as one example. Defensive industrial consolidation is contributing as well: Kone's $34.4 billion combination with TK Elevator reflects the same logic of scale plus cost synergies in defensive end markets supporting high prices. And multiple compression in cyclical sectors has eased, with industrials, materials, and consumer discretionary deals seeing modest expansion in Q1 as expected rate stability set in.

What to Watch Next

A few signals will tell us whether the Q1 multiple environment holds. First, whether the announced large deals (Kone, Sun Pharma, TK Elevator carveouts, Apollo's Forvia transaction) close as structured. Closing risk on large 2026 announcements would chill aggressive bidding in the second half. Second, whether the sponsor-strategic spread compresses or widens. If sponsors keep paying 12x while strategics stay at 8.6x, expect more cross-border strategic activity targeting US assets where the bidder set is weighted toward sponsors. Third, whether direct lending spreads tighten further; cheaper debt would support continued sponsor multiple expansion.